Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Seattle Genetics, Inc.

Bayer Aktiengesellschaft

Bayer Animal Health Gmbh

Ursula Krenz

Hans-Georg Lerchen

Joerg Keldenich

Barbara Albrecht-Küpper

Alexandros Vakalopoulos

Katja Zimmermann

Daniel Meibom

Peter Nell

Karl-Heinz Schlemmer

Elisabeth Perzborn

Jörg Keldenich

Joachim Schuhmacher

Beatrix Stelte-Ludwig

Claudia Hirth-Dietrich

Thomas Krahn

Nicole Diedrichs

Andreas Turberg

Philip Lienau

Ulrich Klar

Gerhard Siemeister

Pierre Wasnaire

Rudolf Schohe-Loop

Carsten Schmeck

Klemens Lustig

Peter Kolkhof

Dirk Kosemund

Nils Griebenow

Wolfgang Schwede

Ulrich Lücking

Hanna Tinel

Axel Kretschmer

Antje Margret Wengner

Mark Jean Gnoth

Sven Golfier

Andrea Rotgeri

Volker Schulze

Ingo Flamme

Johannes Köbberling

Elisabeth Pook

Heiko Schirmer

Joachim Telser

Chantal Fuerstner

Frank Süβmeier

Thomas Neubauer

Sven Wittrock

Donald Bierer

Matthias Beat Wittwer

Sherif El Sheikh

Detlef Stöckigt

Thomas Mondritzki

Dirk Schneider

Carsten Möller

Kirsten Börngen

Frank Süssmeier

Marie-Pierre Collin-Kroepelin

Norbert Witowski

Hana Cernecka

Frank Suessmeier

Karoline Droebner

Michael Brüning

Kirsten Boerngen

Anja Buchmueller

Franziska Schmidt

Guillaume Levilain

Jean Mark Gnoth

Klein Sofia

Robert Fricke

Ildikó Terebesi

Frank Sussmeier

Barbara Albrecht-Kupper

Johannes Kobberling

Barbara Albrecht-Kuepper

The present invention relates to novel halogen-substituted compounds, to processes for their preparation and to their use for controlling animal pests, in particular arthropods and especially insects and arachnids.

Compounds for controlling arthropods

The present invention relates to prodrugs of 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[3-(trifluoromethyl)-pyridin-2-yl ]-1H-1,2,4-triazole-5-carboxamide, 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(trifluoromethyl)-phenyl]-1H-1,2,4-triazole-5-carboxamide and 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-(3-chloropyridin-2-yl)-1H-1,2,4-triazole-5-carboxamide, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Prodrugs of substituted triazole derivatives and uses thereof

The present invention relates to prodrug derivatives of Mps-1 kinase inhibitors, processes for their preparation, and their use for the treatment and/or prophylaxis of diseases.

Prodrug derivatives of substituted triazolopyridines

The invention relates to novel tyrosine based linkers that allow the releasable connection of peptides or proteins with other molecular entities, e.g. polyethylene glycol, to processes for their preparation and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.

Tyrosine based linkers for the releasable connection of peptides

The present application relates to novel substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders.

Substituted dicyanopyridines and use thereof

The invention relates to 17-hydroxy-13-methyl-17-pentafluoroethyl-11-acyloxyalkylenephenyldodecahydrocyclopenta[a]phenanthren-3-one derivatives of the formula I with progesterone-antagonizing action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause, or for fertility control and emergency contraception.

17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases

The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments can occur as monotherapies or in combination with other medication or further therapeutic measures.

N-carboxyalkyl-auristatin and the use thereof

The present application relates to prodrug derivatives of 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.

Dipeptoid prodrugs and their use

The present application relates to novel 6-alkylamino-substituted dicyanopyridines, to their amino acid ester prodrugs, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.

Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof

The present application relates to dipeptide-like prodrug derivatives of 2-amino-6-({[2-(4-chlorophenyl)-1,3-oxazol-4-yl]methyl}sulfanyl)-4-(4-{[2,3-dihydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitrile, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.

Dipeptoid prodrugs and the use thereof

The present application relates to novel derivatives of monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and also to the use of these derivatives for preparing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as, for example, cancerous disorders. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Auristatin derivatives and use thereof

Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs

The present application relates to prodrug derivatives of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.

Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders

Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders

Growing community of inventors

Leichlingen, Germany

Ursula Krenz